05B · Claim Check
Daraxonrasib + chemotherapy · Revolution Medicines RMC-GI-102 · NCT06445062 (our match)
- Readout
- Daraxonrasib + chemotherapy · Revolution Medicines RMC-GI-102 · NCT06445062 (opens another website in a new tab) (our match)
- What the registry or primary source says
- Phase 1/2 platform. Primaries for Subprotocols A to F, including the chemotherapy combination: adverse events and dose-limiting toxicities; response, progression-free and overall survival secondary. N=1,130 (planned); recruiting; primary completion 09.30.2028.
- What the headline says
- Response rate 60.7%, median progression-free survival 12.8 months (n=61)
- Verdict
- Partial
Bookmarks need a Mind Club sign-in. How sign-in works
Read it in Claim Check